The John Theurer Cancer Center Brings Dr. Ami Vaidya to Join Team of Leading Gynecologic Oncologists

HACKENSACK, N.J., June 7 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center announced today the addition of Ami Vaidya, M.D. to the division of gynecologic oncology. Dr. Vaidya is dual-board certified in gynecologic-oncology and obstetrics-gynecology. She brings a world-class education and more than seven years of gynecology experience to the cancer center.  

"We are thrilled to have Dr. Vaidya join our expert gynecologic oncology team," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chairman and Executive Administrative Director, the John Theurer Cancer Center. "Her expertise in both the clinic and in research bolsters our strong team that has begun to take a leadership role in the national fight against cancers for women."  

Dr. Vaidya completed her residency at New York University and her fellowship at Harvard Medical School Massachusetts General. She then served as Assistant Professor of Obstetrics and Gynecology at the Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School.  

Dr. Vaidya's areas of focus have included uterine papillary serous carcinoma and signal transducers and activators in drug-resistant ovarian cancer. She has been published in numerous oncology journals, including International Journal of Gynecologic Oncology and Gynecologic Oncology. Additionally, she has presented her research at a number of medical meetings including the annual meeting of the Society of Gynecologic Oncologists. Of her many honors, she received the notable New England Association of Gynecologic Oncologists Fellow Research Award and the New York University Resident Clinical Research Award.  

"Dr. Vaidya has an extensive background in gynecologic oncology that will help the John Theurer Cancer Center continue to contribute to innovative research and provide the highest level of patient care," said Dr. Pecora.

The Division of Gynecologic Oncology at the John Theurer Cancer strives to provide extraordinary, personalized care to women with all cancer types affecting the reproductive system.  For instance, the John Theurer Cancer Center is one of only twenty centers in the country selected to train physicians for the revolutionary daVinci® surgical robot, which makes gynecologic cancer surgery easier and safer for patients. With five daVinci® robots, the cancer center offers the most in New Jersey. Additionally, the team has been working with GVAX, a vaccine modulated therapy that has been used successfully for other types of cancer, for adoption with ovarian cancer.

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancer. The 15 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of after care services that distinguish John Theurer Cancer Center from other facilities. For more information, visit the John Theurer Cancer Center's website at www.humccancer.org.  

SOURCE The John Theurer Cancer Center at Hackensack University Medical Center

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED